GlassScriptPhysician profile
Melvin A Yeshnik
NPI 1124012166
$315.82
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $13.99 · 2021: $89.98 · 2022: $88.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $110.35 | 2021-2022 | |
| Duchesnay USA Incorporated | $57.92 | 2019 | |
| Allergan, INC. | $41.34 | 2019 | |
| Myovant Sciences INC. | $32.70 | 2021 | |
| Amag Pharmaceuticals, INC. | $23.96 | 2019 | |
| Hologic Sales and Service, LLC | $22.34 | 2021 | |
| Avion Pharmaceuticals | $13.99 | 2020 | |
| Organon LLC | $13.22 | 2021-2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Yeshnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.